Regulatory Phase I Clinical Trials

SGS is one of the world’s leading early clinical development contract research organizations.

Our clinical Phase I Unit provides clients with a full range of clinical research services compliant with EMEA and FDA requirements to facilitate your “go/no go” decisions during clinical development. We offer a large range of Phase I studies including drug interaction (DDI), TQT/QTc, as well as BA/BE and ADME/pharmacokinetic studies.

TQT/QTc trials

SGS performs five to six TQT/QTc studies per year with an average of 24,000 ECGs per trial. We offer:

With partners specializing in cardiac data reading (ECG/Holter), we have developed a strong expertise in providing high-quality ECG reading and analysis in QT prolongation and safety pharmacology studies to the pharmaceutical and biotech industries.